Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
98.6M
-
Number of holders
-
98
-
Total 13F shares, excl. options
-
65.4M
-
Shares change
-
-1.14M
-
Total reported value, excl. options
-
$358M
-
Value change
-
-$3M
-
Put/Call ratio
-
0.32
-
Number of buys
-
45
-
Number of sells
-
-42
-
Price
-
$5.48
Significant Holders of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) as of Q4 2023
122 filings reported holding SPRY - ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q4 2023.
ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) has 98 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 65.4M shares
of 98.6M outstanding shares and own 66.33% of the company stock.
Largest 10 shareholders include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (11.1M shares), RA CAPITAL MANAGEMENT, L.P. (9.46M shares), ORBIMED ADVISORS LLC (9.24M shares), FRANKLIN RESOURCES INC (4.1M shares), SR ONE CAPITAL MANAGEMENT, LP (4.01M shares), Charles Schwab Trust Co (4M shares), K2 PRINCIPAL FUND, L.P. (3.05M shares), BlackRock Inc. (2.64M shares), VANGUARD GROUP INC (2.11M shares), and BAKER BROS. ADVISORS LP (2.01M shares).
This table shows the top 98 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.